Abstract:Background: The COVID-19 pandemic affected healthcare systems, tumbling cancer screening programs and increasing fear of infection among medical facilities users. We hypothesized that the pandemic negatively impacted the clinical outcomes of patients (pts) with advanced breast cancer (ABC). The COVID19-ABC study aims to assess the influence of the pandemic on disease volume, severity, and clinical complications at diagnosis and during 1st year of ABC. Methods: Single-center, retrospective, quasi-experimental study with historical control. We included women treated for unresectable/metastatic recurrent or stage IV de novo ABC in a Belgian cancer center. Pts were eligible if ABC was diagnosed between 1/Jun/2020-30/Nov/2021 - pandemic exposure (Exp) cohort - or between 1/Jun/2017-30/Nov/2018 - historical (Hist) cohort. We collected data from medical records for baseline characteristics and study outcomes: proportion of oligometastatic disease (OMD) at ABC diagnosis, and proportion of visceral crisis and disease-related serious clinical events during the 1st month and between 1-12 months after ABC diagnosis. We compared baseline variables between the two cohorts using χ2 test for frequencies and Wilcoxon rank-sum test for continuous variables. We performed a pre-planned subgroup analysis by year of pandemic, immunohistochemistry (IHC) subtype, and recurrent vs de novo ABC. Univariate and multivariate backward stepwise logistic regressions were used to determine the odds ratio (OR) and the 95% confidence interval (CI) of the association of exposure to the pandemic with study outcomes, controlling for confounders. Results: We included 150 pts, 74 in Exp and 76 in Hist cohort. Age and proportion of de novo ABC and triple-negative breast cancer (TNBC) were numerically higher, while comorbidities and Ki67 index were significantly higher among patients in the Exp cohort (Table 1). Pts in the Exp cohort had a significantly higher risk of visceral crisis during the 1st month of ABC (28.4% vs 15.8%; OR 4.24, 95% CI, 1.45-12.39, adjusted for histology grade and recurrent vs de novo), with similar trend between 1-12 months of ABC (19.4% vs 12.7%, OR 1.66, 95% CI, 0.67-4.13). Visceral crisis tended to be more common in patients diagnosed in the 2nd vs 1st year of the pandemic (35.7% vs 26.7%, p=0.50). We observed higher proportions of visceral crisis in the Exp cohort for pts with recurrent ABC (36.5% vs 17.7%, p=0.02), HER2+ (66.7% vs 10.0%, p=0.01), and TNBC (40.0% vs 18.2%, p=0.21) IHC subtypes. The most common indicators of visceral crisis in the Exp cohort were symptomatic brain metastases (33.3%), malignant hypercalcemia (28.6%), and liver metastases with hepatic tests abnormalities (23.8%). OMD at presentation (35.1% vs 36.8%, p=0.83) and disease-related serious clinical events during 1st month (31.1% vs 37.3%, p=0.42) and between 1-12 months (31.9% vs 34.2%, p=0.77) did not differ between cohorts. Conclusion: Our study reports a more clinically severe presentation of ABC during the pandemic compared to historical control. This emerged particularly in recurrences and in more aggressive disease subtypes such as HER2+ and TNBC, suggesting a later diagnosis of ABC during the pandemic. These findings require validation in a larger sample, and longer follow-up is needed to assess survival impact. Table 1. Baseline clinicopathologic characteristics at diagnosis of advanced breast cancer (missing values: 1 for menopausal status, 21 for grade). Citation Format: Diogo Martins-Branco, Véronique Debien, Michel Moreau, Giovanna Pinna, Ottavia Amato, François Cherifi, Guilherme Nader-Marta, Marianne Paesmans, Evandro de Azambuja. Impact of COVID-19 Pandemic on the Disease Volume, Severity and Clinical Complications at Diagnosis and During First Year of Advanced Breast Cancer: COVID19-ABC Quasi-Experimental Study [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl) nr PO2-10-11.

COVID-19 Outbreak Impact on Cancer Multidisciplinary Team Meetings. A Multicenter French Experience

Virtually the same? Examining the impact of the COVID-19 related shift to virtual lung cancer multidisciplinary team meetings in the UK National Health Service: a mixed methods study

A qualitative study of teleconsultation practices among French oncologists in a post-COVID-19 period

The Impact of the COVID-19 Pandemic on Multidisciplinary Clinics: A High-Volume Pancreatic Cancer Center Experience

A two-center experience: The impact of COVID-19 on two brachytherapy programs in Ontario - virtual care, service suspension and radiation therapy workflow

Analysis of communication styles underpinning clinical decision-making in cancer multidisciplinary team meetings

Impact of the Early Phase of the COVID-19 Pandemic on the Quality of Care for Colorectal and Anal Cancers at Comprehensive Cancer Centers on Two Continents

Management of Patients With Hematologic Malignancies During the COVID-19 Pandemic: Practical Considerations and Lessons to Be Learned

Perspectives on the COVID-19 pandemic impact on cardio-oncology: results from the COVID-19 International Collaborative Network survey

Impact of Multiple COVID-19 Waves on Gynaecological Cancer Services in the UK

Factors influencing the quality and functioning of oncological multidisciplinary team meetings: results of a systematic review

Rising incidence of late stage breast cancer after COVID-19 outbreak. Real-world data from the Italian COVID-DELAY study

Abstract PO-093: The impact of the COVID-19 pandemic on care delivery and quality of life in lung cancer surgery

Abstract PO2-10-11: Impact of COVID-19 Pandemic on the Disease Volume, Severity and Clinical Complications at Diagnosis and During First Year of Advanced Breast Cancer: COVID19-ABC Quasi-Experimental Study

Abstract PO-007: Breast cancer management during COVID-19 outbreak: Learned lessons

Impact of the First Wave of COVID-19 on Pediatric Oncology and Hematology: A Report from the French Society of Pediatric Oncology

COVID-19: Impact on Cancer Workforce and Delivery of Care

Impact of COVID-19 on patients with metastatic breast cancer: REthink Access to Care and Treatment survey results

Cloud platform to improve efficiency and coverage of asynchronous multidisciplinary team meetings for patients with digestive tract cancer

Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus

Die COVID-19-Pandemie und ihr Einfluss auf die ärztliche Weiterbildung in der Kopf-Hals-Onkologie